A Multi-centre, Randomized, Controlled Trial on Coaching and Telemonitoring in Patients with Cystic Fibrosis: ConneCT CF

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2021 Apr 22

PMID 33882893

Citations 10

Authors

Stephanie Thee

Mirjam Stahl

Rainald Fischer

Sivagurunathan Sutharsan

Manfred Ballmann

Axel Muller

Daniel Lorenz

Dominika Urbanski-Rini

Franziska Puschner

Volker Eric Amelung

Carola Fuchs

Marcus Alexander Mall

Affiliations

Soon will be listed here.

Abstract

Background: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in CF care. We implement a randomized controlled trial to evaluate efficacy of telemonitoring of adherence, lung function, and health condition in combination with behavior change interventions using innovative digital technologies.

Methods: This is a multi-centre, randomized, controlled, non-blinded trial aiming to include 402 patients ≥ 12 years-of-age with CF. A standard-of-care arm is compared to an arm receiving objective, continuous monitoring of adherence to inhalation therapies, weekly home spirometry using electronic devices with data transmission to patients and caring physicians combined with video-conferencing, a self-management app and professional telephone coaching. The duration of the intervention phase is 18 months. The primary endpoint is time to the first protocol-defined pulmonary exacerbation. Secondary outcome measures include number of and time between pulmonary exacerbations, adherence to inhalation therapy, changes in forced expiratory volume in 1 s from baseline, number of hospital admissions, and changes in health-related quality of life. CF-associated medical treatment and care, and health care related costs will be assessed by explorative analysis in both arms.

Discussion: This study offers the opportunity to evaluate the effect of adherence interventions using telemedicine capable devices on adherence and lung health, possibly paving the way for implementation of telemedicine in routine care for patients with CF.

Trial Registration: This study has been registered with the German Clinical Trials Register (Identifier: DRKS00024642, date of registration 01 Mar 2021, URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024642 ).

Citing Articles

Using Community Engagement to Create a Telecoaching Intervention to Improve Self-Management in Adolescents and Young Adults With Cystic Fibrosis: Qualitative Study.

Duncan C, Muther E, Lindwall J, Durkin K, Ruvalcaba E, Williamson E J Particip Med. 2025; 17:e49941.

PMID: 39832355 PMC: 11791463. DOI: 10.2196/49941.

Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review.

Lakhani A, Clementina R, Siddiqua Z, Shroff S, Bhavanam S, Pandya M Cureus. 2024; 16(10):e71913.

PMID: 39564025 PMC: 11576056. DOI: 10.7759/cureus.71913.

Nebuliser systems for drug delivery in cystic fibrosis.

Stanford G, Morrison L, Brown C Cochrane Database Syst Rev. 2023; 11:CD007639.

PMID: 37942828 PMC: 10633867. DOI: 10.1002/14651858.CD007639.pub3.

Telemedicine and Its Application in Cystic Fibrosis.

Fainardi V, Capoferri G, Tornesello M, Pisi G, Esposito S J Pers Med. 2023; 13(7).

PMID: 37511654 PMC: 10381340. DOI: 10.3390/jpm13071041.

A Participatory Approach Involving Patients with Cystic Fibrosis and Healthcare Professionals for the Co-Design of an Adherence-Enhancing Intervention Toolkit.

Viprey M, Mougeot F, Dima A, Haesebaert J, Occelli P, Durieu I Patient Prefer Adherence. 2023; 17:995-1004.

PMID: 37063606 PMC: 10103710. DOI: 10.2147/PPA.S389792.

References

Hind D, Drabble S, Arden M, Mandefield L, Waterhouse S, Maguire C . Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulm Med. 2019; 19(1):77. PMC: 6458785. DOI: 10.1186/s12890-019-0834-6. View

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

Lechtzin N, Mayer-Hamblett N, West N, Allgood S, Wilhelm E, Khan U . Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. Am J Respir Crit Care Med. 2017; 196(9):1144-1151. PMC: 5694835. DOI: 10.1164/rccm.201610-2172OC. View

Ozsezen B, Emiralioglu N, Tural D, Sunman B, Buyuksahin H, Yalcin E . Telephone surveillance during the COVID-19 pandemic: Is it a helpful diagnostic tool for detecting acute pulmonary exacerbations in children with chronic lung disease?. J Telemed Telecare. 2020; 28(9):694-702. DOI: 10.1177/1357633X20972008. View

Flume P, OSullivan B, Robinson K, Goss C, Mogayzel Jr P, Willey-Courand D . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176(10):957-69. DOI: 10.1164/rccm.200705-664OC. View

Kreimeier S, Greiner W . EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set. Value Health. 2019; 22(1):31-37. DOI: 10.1016/j.jval.2018.11.001. View

Bell S, Mall M, Gutierrez H, Macek M, Madge S, Davies J . The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019; 8(1):65-124. PMC: 8862661. DOI: 10.1016/S2213-2600(19)30337-6. View

Savage E, Beirne P, Ni Chroinin M, Duff A, Fitzgerald T, Farrell D . Self-management education for cystic fibrosis. Cochrane Database Syst Rev. 2014; (9):CD007641. PMC: 6481678. DOI: 10.1002/14651858.CD007641.pub3. View

List R, Compton M, Soper M, Bruschwein H, Gettle L, Bailey M . Preserving Multidisciplinary Care Model and Patient Safety During Reopening of Ambulatory Cystic Fibrosis Clinic for Nonurgent Care: A Hybrid Telehealth Model. Telemed J E Health. 2020; 27(2):193-199. DOI: 10.1089/tmj.2020.0247. View

10.

Wenninger K, Aussage P, Wahn U, Staab D . The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Qual Life Res. 2003; 12(1):77-85. DOI: 10.1023/a:1022011704399. View

11.

Pietsch K, Hoyler A, Fruhe B, Kruse J, Schulte-Korne G, Allgaier A . [Early detection of major depression in paediatric care: validity of the beck depression inventory-second edition (BDI-II) and the beck depression inventory-fast screen for medical patients (BDI-FS)]. Psychother Psychosom Med Psychol. 2012; 62(11):418-24. DOI: 10.1055/s-0032-1314869. View

12.

Shakkottai A, Kaciroti N, Kasmikha L, Nasr S . Impact of home spirometry on medication adherence among adolescents with cystic fibrosis. Pediatr Pulmonol. 2018; 53(4):431-436. DOI: 10.1002/ppul.23950. View

13.

Kuhner C, Burger C, Keller F, Hautzinger M . [Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples]. Nervenarzt. 2006; 78(6):651-6. DOI: 10.1007/s00115-006-2098-7. View

14.

van Horck M, Winkens B, Wesseling G, van Vliet D, van de Kant K, Vaassen S . Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function. Sci Rep. 2017; 7(1):12350. PMC: 5617859. DOI: 10.1038/s41598-017-10945-3. View

15.

Mall M, Mayer-Hamblett N, Rowe S . Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med. 2019; 201(10):1193-1208. PMC: 7233349. DOI: 10.1164/rccm.201910-1943SO. View

16.

Murgia F, Cilli M, Renzetti E, Popa N, Romano T, Alghisi F . [Economic evaluation of telehomecare in chronic lung diseases]. Clin Ter. 2011; 162(2):e43-9. View

17.

Kerem E, Reisman J, Corey M, Canny G, Levison H . Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326(18):1187-91. DOI: 10.1056/NEJM199204303261804. View

18.

Chrysochoou E, Hatziagorou E, Kirvassilis F, Tsanakas J . Telephone monitoring and home visits significantly improved the quality of life, treatment adherence and lung function in children with cystic fibrosis. Acta Paediatr. 2017; 106(11):1882. DOI: 10.1111/apa.13996. View

19.

Grzincich G, Gagliardini R, Bossi A, Bella S, Cimino G, Cirilli N . Evaluation of a home telemonitoring service for adult patients with cystic fibrosis: a pilot study. J Telemed Telecare. 2010; 16(7):359-62. DOI: 10.1258/jtt.2010.091006. View

20.

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View